Yuhan Corporation generates 21 blockbuster drugs recording over KRW 10 billion sales

It was observed Yuhan Corporation made KRW 140 billion sales with the hepatitis B treatment ‘Viread’ last year.

Moreover, the company was recorded to spend 6.5% of sales, KRW 85.2 billion, into R&D.

With Viread which recorded KRW 140 billion sales from the pharmaceutical business last year, Yuhan Corporation announced the total 21 products(Trajenta, Twynsta, Atorva, Prevenar, etc) exceeded KR...